TIA
MCID: TRN015
MIFTS: 62

Transient Cerebral Ischemia (TIA)

Categories: Blood diseases, Cardiovascular diseases, Neuronal diseases

Aliases & Classifications for Transient Cerebral Ischemia

MalaCards integrated aliases for Transient Cerebral Ischemia:

Name: Transient Cerebral Ischemia 12 55 15 72
Transient Ischemic Attack 12 54 55 6 43 17 72
Transient Ischemic Attacks 12 15
Tia - Transient Ischaemic Attack 12
Transient Cerebral Ischaemia 12
Ischemic Attack, Transient 44
Tia 12

Classifications:



External Ids:

Disease Ontology 12 DOID:224
MeSH 44 D002546
NCIt 50 C50781
SNOMED-CT 68 38609002
ICD10 33 G45.9
UMLS 72 C0007787 C0917805

Summaries for Transient Cerebral Ischemia

MedlinePlus : 43 A transient ischemic attack (TIA) is a stroke that lasts only a few minutes. It happens when the blood supply to part of the brain is briefly blocked. Symptoms of a TIA are like other stroke symptoms, but do not last as long. They happen suddenly, and include Numbness or weakness, especially on one side of the body Confusion or trouble speaking or understanding speech Trouble seeing in one or both eyes Difficulty walking Dizziness Loss of balance or coordination Most symptoms of a TIA disappear within an hour, although they may last for up to 24 hours. Because you cannot tell if these symptoms are from a TIA or a stroke, you should go to the hospital right away. TIAs are often a warning sign for future strokes. Taking medicine, such as blood thinners, may reduce your risk of a stroke. Your doctor might also recommend surgery. You can also help lower your risk by having a healthy lifestyle. This includes not smoking, not drinking too much, eating a healthy diet, and exercising. It is also important to control other health problems, such as high blood pressure and cholesterol. NIH: National Institute of Neurological Disorders and Stroke

MalaCards based summary : Transient Cerebral Ischemia, also known as transient ischemic attack, is related to ischemia and carotid artery occlusion, and has symptoms including seizures, tremor and angina pectoris. An important gene associated with Transient Cerebral Ischemia is NOTCH3 (Notch Receptor 3), and among its related pathways/superpathways are G-protein signaling Ras family GTPases in kinase cascades (scheme) and Toxoplasmosis. The drugs Aspirin and Irbesartan have been mentioned in the context of this disorder. Affiliated tissues include brain, heart and testes, and related phenotype is nervous system.

Disease Ontology : 12 A brain ischemia that is characterized by ischemia of brief duration and without resultant tissue death.

NINDS : 54 A transient ischemic attack (TIA) is a transient stroke that lasts only a few minutes. It occurs when the blood supply to part of the brain is briefly interrupted. TIA symptoms, which usually occur suddenly, are similar to those of stroke but do not last as long. Most symptoms of a TIA disappear within an hour, although they may persist for up to 24 hours. Symptoms can include: numbness or weakness in the face, arm, or leg, especially on one side of the body; confusion or difficulty in talking or understanding speech; trouble seeing in one or both eyes; and difficulty with walking, dizziness, or loss of balance and coordination.

Wikipedia : 75 A transient ischemic attack (TIA) is a brief episode of neurological dysfunction caused by loss of blood... more...

Related Diseases for Transient Cerebral Ischemia

Diseases related to Transient Cerebral Ischemia via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 458, show less)
# Related Disease Score Top Affiliating Genes
1 ischemia 30.9 MAP2 HSPA4 HSPA1A CASP3
2 carotid artery occlusion 30.0 MAP2 HSPA1A APOH
3 cytomegalovirus infection 29.9 IL1B CCL2 CASP3
4 spinal cord infarction 29.4 MTHFR APOH
5 placenta disease 29.0 MTHFR IL1B APOH
6 intracranial hypertension 29.0 MTHFR IL1B APOH
7 migraine with or without aura 1 28.3 NOTCH3 MTHFR APOH
8 stroke, ischemic 27.2 NOTCH3 MTHFR MAP2 HSPA4 CASP3 APOH
9 mini stroke 11.9
10 vertebrobasilar insufficiency 11.7
11 paresthesia 11.7
12 essential thrombocythemia 11.7
13 moyamoya disease 1 11.7
14 carotid artery disease 11.7
15 sneddon syndrome 11.5
16 moyamoya disease 2 11.5
17 moyamoya disease 6 with or without achalasia 11.5
18 cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 1 11.4
19 buerger disease 11.4
20 telangiectasia, hereditary hemorrhagic, type 4 11.4
21 moyamoya disease 5 11.4
22 aganglionosis, total intestinal 11.3
23 cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 2 11.2
24 cerebral artery occlusion 10.8
25 arteries, anomalies of 10.5
26 atrial fibrillation 10.5
27 brain edema 10.4
28 thrombocytosis 10.3
29 cardiac arrest 10.3
30 ataxia and polyneuropathy, adult-onset 10.3
31 papilledema 10.3
32 intermediate coronary syndrome 10.3
33 sickle cell disease 10.3
34 sleep apnea 10.3
35 hyperglycemia 10.2
36 purulent labyrinthitis 10.2 IL1B CCL2
37 meningitis 10.2
38 thrombophilia due to thrombin defect 10.2
39 peripheral vascular disease 10.2
40 pure autonomic failure 10.2
41 headache 10.2
42 mesenteric vascular occlusion 10.2 ODC1 MTHFR
43 hydrops, lactic acidosis, and sideroblastic anemia 10.2
44 apnea, obstructive sleep 10.2
45 atrial standstill 1 10.2
46 hemiplegia 10.2
47 heart septal defect 10.2
48 brain stem infarction 10.2
49 kidney disease 10.2
50 chronic kidney disease 10.2
51 pathologic nystagmus 10.2
52 alcohol use disorder 10.2
53 specific language disorder 10.2
54 amnestic disorder 10.2
55 48,xyyy 10.2
56 endocarditis 10.1
57 brucellosis 10.1
58 hereditary hemorrhagic telangiectasia 10.1
59 telangiectasis 10.1
60 dilated cardiomyopathy 10.1
61 dementia 10.1
62 atrial heart septal defect 10.1
63 sleep disorder 10.1
64 peripheral nervous system disease 10.1
65 neuropathy 10.1
66 eagle syndrome 10.1
67 encephalopathy 10.1
68 fainting 10.1
69 obsolete: papillary fibroelastoma of the heart 10.1
70 retinitis pigmentosa 73 10.1 IL1B CCL2
71 cerebral amyloid angiopathy, cst3-related 10.1
72 fabry disease 10.1
73 lipid metabolism disorder 10.1
74 trypanosomiasis 10.1 ODC1 IL1B CCL2
75 meningioma, radiation-induced 10.1
76 meningioma, familial 10.1
77 spinal meningioma 10.1
78 visual epilepsy 10.1
79 secretory meningioma 10.1
80 lymphoplasmacyte-rich meningioma 10.1
81 seizure disorder 10.1
82 asplenia, isolated congenital 10.0
83 angina pectoris 10.0
84 peripheral artery disease 10.0
85 migraine with aura 10.0
86 retinal ischemia 10.0
87 post-traumatic stress disorder 10.0
88 thrombophilia 10.0
89 congestive heart failure 10.0
90 acute stress disorder 10.0
91 herpes zoster 10.0
92 pulmonary embolism 10.0
93 47,xyy 10.0
94 syncope 10.0
95 autoimmune disease 10.0
96 systemic lupus erythematosus 10.0
97 rheumatoid arthritis 10.0
98 sarcoidosis 1 10.0
99 takayasu arteritis 10.0
100 pulmonary arteriovenous fistulas 10.0
101 acute promyelocytic leukemia 10.0
102 encephalopathy, progressive, early-onset, with episodic rhabdomyolysis 10.0
103 infective endocarditis 10.0
104 stuttering 10.0
105 cryptococcal meningitis 10.0
106 meningoencephalitis 10.0
107 nephrotic syndrome 10.0
108 locked-in syndrome 10.0
109 subclavian steal syndrome 10.0
110 basilar artery occlusion 10.0
111 polyneuropathy 10.0
112 mental depression 10.0
113 mitral valve stenosis 10.0
114 sagittal sinus thrombosis 10.0
115 protein c deficiency 10.0
116 myopathy 10.0
117 coronary stenosis 10.0
118 aortic valve insufficiency 10.0
119 hemolytic anemia 10.0
120 scotoma 10.0
121 hypertrophic cardiomyopathy 10.0
122 pulmonary arteriovenous malformation 10.0
123 thunderclap headache 10.0
124 autonomic dysfunction 10.0
125 chronic enteropathy associated with slco2a1 gene 10.0
126 pik3ca-related overgrowth syndrome 10.0
127 rare surgical neurologic disease 10.0
128 occlusion precerebral artery 10.0 MAP2 HSPA1A CASP3
129 optic atrophy 1 10.0
130 3-methylglutaconic aciduria, type iii 10.0
131 frontotemporal dementia 10.0
132 orthostatic intolerance 10.0
133 vascular disease 10.0
134 lactic acidosis 10.0
135 cerebrovascular disease 10.0
136 hypoglycemia 10.0
137 amaurosis fugax 10.0
138 aneurysm 10.0
139 brain injury 10.0
140 hypertriglyceridemia, familial 10.0
141 schistosoma mansoni infection, susceptibility/ 10.0
142 homocysteinemia 10.0
143 coronary heart disease 1 10.0
144 paragonimiasis 10.0
145 arteriovenous malformation 10.0
146 clonorchiasis 10.0
147 schistosomiasis 10.0
148 echinococcosis 10.0
149 glioblastoma multiforme 10.0
150 purpura 10.0
151 heart valve disease 10.0
152 movement disease 10.0
153 neurotic disorder 10.0
154 vascular dementia 10.0
155 fascioliasis 10.0
156 carotid artery dissection 10.0
157 glioblastoma 10.0
158 depression 10.0
159 atrial fibrillation and stroke 10.0
160 myoclonus 10.0
161 respiratory system disease 9.9 IL1B CCL2 CASP3
162 hypoxia 9.9
163 abducens palsy 9.9
164 progressive familial heart block, type ia 9.9
165 carpal tunnel syndrome 9.9
166 multiple sclerosis 9.9
167 esophageal cancer 9.9
168 spondyloepiphyseal dysplasia with congenital joint dislocations 9.9
169 spondylosis, cervical 9.9
170 strabismus 9.9
171 varicose veins 9.9
172 acrocallosal syndrome 9.9
173 arterial calcification, generalized, of infancy, 1 9.9
174 chondrosarcoma 9.9
175 hemolytic uremic syndrome, atypical 1 9.9
176 lymphoma, hodgkin, classic 9.9
177 intracranial hypertension, idiopathic 9.9
178 pulmonary hypoplasia, primary 9.9
179 danon disease 9.9
180 sarcoma, synovial 9.9
181 moyamoya disease 4 with short stature, hypergonadotropic hypogonadism, and facial dysmorphism 9.9
182 charcot-marie-tooth disease, x-linked dominant, 1 9.9
183 hemophilia b 9.9
184 mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes 9.9
185 progressive familial heart block, type ib 9.9
186 cerebral amyloid angiopathy, app-related 9.9
187 aneurysmal bone cysts 9.9
188 pulmonary disease, chronic obstructive 9.9
189 major depressive disorder 9.9
190 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 9.9
191 intraocular pressure quantitative trait locus 9.9
192 microvascular complications of diabetes 5 9.9
193 beta-thalassemia 9.9
194 muscle hypertrophy 9.9
195 peripartum cardiomyopathy 9.9
196 membranous nephropathy 9.9
197 atrial fibrillation, familial, 15 9.9
198 striatal degeneration, autosomal dominant 2 9.9
199 aspiration pneumonia 9.9
200 chronic venous insufficiency 9.9
201 fibroma 9.9
202 amusia 9.9
203 colitis 9.9
204 ptosis 9.9
205 left ventricular noncompaction 9.9
206 cysticercosis 9.9
207 venous insufficiency 9.9
208 osteomyelitis 9.9
209 aortic atherosclerosis 9.9
210 thalassemia 9.9
211 left bundle branch hemiblock 9.9
212 pre-eclampsia 9.9
213 sarcoma 9.9
214 primary hyperparathyroidism 9.9
215 orbital cellulitis 9.9
216 alternating exotropia 9.9
217 exotropia 9.9
218 hemopericardium 9.9
219 mitral valve insufficiency 9.9
220 autonomic neuropathy 9.9
221 hypertensive retinopathy 9.9
222 presbyopia 9.9
223 pericardial effusion 9.9
224 mononeuropathy 9.9
225 allergic hypersensitivity disease 9.9
226 leukemia 9.9
227 hemolytic-uremic syndrome 9.9
228 quadriplegia 9.9
229 branch retinal artery occlusion 9.9
230 focal segmental glomerulosclerosis 9.9
231 acute cystitis 9.9
232 right bundle branch block 9.9
233 hyperparathyroidism 9.9
234 poems syndrome 9.9
235 generalized anxiety disorder 9.9
236 cholesterol embolism 9.9
237 angioedema 9.9
238 cystitis 9.9
239 calcinosis 9.9
240 melanoma 9.9
241 cerebral palsy 9.9
242 myeloproliferative neoplasm 9.9
243 hemangioma 9.9
244 tic disorder 9.9
245 hemoglobinopathy 9.9
246 glomerulonephritis 9.9
247 anuria 9.9
248 substance abuse 9.9
249 acute kidney failure 9.9
250 cellulitis 9.9
251 cerebral arterial disease 9.9
252 choriocarcinoma 9.9
253 plasmacytoma 9.9
254 pituitary adenoma 9.9
255 spindle cell sarcoma 9.9
256 radiculopathy 9.9
257 uremia 9.9
258 prosopagnosia 9.9
259 liver cirrhosis 9.9
260 aortic disease 9.9
261 dystonia 9.9
262 silent myocardial infarction 9.9
263 paraplegia 9.9
264 lymphopenia 9.9
265 severe combined immunodeficiency 9.9
266 mitochondrial myopathy 9.9
267 mitochondrial metabolism disease 9.9
268 thyroiditis 9.9
269 peptic ulcer disease 9.9
270 petroclival meningioma 9.9
271 end stage renal failure 9.9
272 cocaine abuse 9.9
273 osteochondrosis 9.9
274 mediastinitis 9.9
275 retinal artery occlusion 9.9
276 collagen disease 9.9
277 ulcerative colitis 9.9
278 chickenpox 9.9
279 speech disorder 9.9
280 erythromelalgia 9.9
281 homocystinuria 9.9
282 mechanical strabismus 9.9
283 cannabis abuse 9.9
284 hemophilia 9.9
285 mitochondrial disorders 9.9
286 afibrinogenemia 9.9
287 carotidynia 9.9
288 cor triatriatum 9.9
289 coronary artery aneurysm 9.9
290 germ cells tumors 9.9
291 hemiplegic migraine 9.9
292 herpes zoster ophthalmicus 9.9
293 mast cell activation syndrome 9.9
294 phace syndrome 9.9
295 primary angiitis of the central nervous system 9.9
296 pseudobulbar affect 9.9
297 st anthony's fire 9.9
298 supranuclear ocular palsy 9.9
299 spinal cord injury 9.9
300 tremor 9.9
301 rare cardiac tumor 9.9
302 superficial siderosis 9.9
303 lymphomatous meningitis 9.9
304 thrombotic microangiopathy 9.9
305 cardiac arrhythmia 9.8
306 fibromuscular dysplasia 9.8
307 attention deficit-hyperactivity disorder 9.8
308 hypercholesterolemia, familial, 1 9.8
309 hyperlipoproteinemia, type iv 9.8
310 neutrophil migration 9.8
311 retinoblastoma 9.8
312 proteasome-associated autoinflammatory syndrome 1 9.8
313 yemenite deaf-blind hypopigmentation syndrome 9.8
314 mitral valve prolapse 2 9.8
315 anxiety 9.8
316 aortic valve disease 2 9.8
317 alacrima, achalasia, and mental retardation syndrome 9.8
318 thrombocytopenia 6 9.8
319 helix syndrome 9.8
320 chlamydia pneumonia 9.8
321 fetal alcohol syndrome 9.8
322 fetal alcohol spectrum disorder 9.8
323 limb ischemia 9.8
324 aphasia 9.8
325 brain meningioma 9.8
326 porencephaly 9.8
327 thrombosis 9.8
328 glucose intolerance 9.8
329 intracranial aneurysm 9.8
330 chlamydia 9.8
331 retinal microaneurysm 9.8
332 vertebral artery occlusion 9.8
333 tetanus 9.8
334 hypertensive heart disease 9.8
335 cerebral atherosclerosis 9.8
336 carotid stenosis 9.8
337 transient global amnesia 9.8
338 patent foramen ovale 9.8
339 hypothyroidism 9.8
340 thrombocytopenia 9.8
341 pneumothorax 9.8
342 focal epilepsy 9.8
343 arteriosclerosis 9.8
344 protein s deficiency 9.8
345 dermoid cyst 9.8
346 cystic teratoma 9.8
347 cockayne syndrome 9.8
348 antiphospholipid syndrome 9.8
349 middle cerebral artery infarction 9.8
350 anovulation 9.8
351 familial retinoblastoma 9.8
352 mature teratoma 9.8
353 adenoma 9.8
354 b-cell lymphoma 9.8
355 vasculitis 9.8
356 cerebellar degeneration 9.8
357 cerebral aneurysms 9.8
358 cerebral arteriosclerosis 9.8
359 interatrial communication 9.8
360 atrial septal aneurysm 9.8
361 aortic aneurysm, familial abdominal, 1 9.8
362 alcohol dependence 9.8
363 atherosclerosis susceptibility 9.8
364 aortic valve disease 1 9.8
365 renal cell carcinoma, nonpapillary 9.8
366 platelet aggregation, spontaneous 9.8
367 polykaryocytosis inducer 9.8
368 sturge-weber syndrome 9.8
369 thrombophilia due to activated protein c resistance 9.8
370 argininosuccinic aciduria 9.8
371 lung cancer 9.8
372 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 9.8
373 hydrocephalus, congenital, 1 9.8
374 hydrocephalus, normal-pressure 9.8
375 netherton syndrome 9.8
376 ocular motor apraxia 9.8
377 body mass index quantitative trait locus 1 9.8
378 creatinine clearance quantitative trait locus 9.8
379 resting heart rate, variation in 9.8
380 aspirin resistance 9.8
381 myocardial infarction 9.8
382 colorectal cancer 2 9.8
383 diabetes mellitus, ketosis-prone 9.8
384 cyanosis, transient neonatal 9.8
385 hyperlipoproteinemia, type iii 9.8
386 speech and communication disorders 9.8
387 deficiency anemia 9.8
388 restless legs syndrome 9.8
389 meningovascular neurosyphilis 9.8
390 anosognosia 9.8
391 agraphia 9.8
392 asymptomatic neurosyphilis 9.8
393 viral meningitis 9.8
394 siderosis 9.8
395 thrombotic thrombocytopenic purpura 9.8
396 filariasis 9.8
397 gastric ulcer 9.8
398 hydrocephalus 9.8
399 disseminated intravascular coagulation 9.8
400 adult respiratory distress syndrome 9.8
401 heart disease 9.8
402 lyme disease 9.8
403 iron deficiency anemia 9.8
404 coronary artery anomaly 9.8
405 bell's palsy 9.8
406 migraine without aura 9.8
407 sick sinus syndrome 9.8
408 facial paralysis 9.8
409 iritis 9.8
410 encephalomalacia 9.8
411 hepatitis 9.8
412 spondylosis 9.8
413 generalized atherosclerosis 9.8
414 iron metabolism disease 9.8
415 astrocytoma 9.8
416 oligodendroglioma 9.8
417 mood disorder 9.8
418 aortic aneurysm 9.8
419 intermittent claudication 9.8
420 tricuspid valve insufficiency 9.8
421 syphilis 9.8
422 systemic scleroderma 9.8
423 intracranial thrombosis 9.8
424 intracranial embolism 9.8
425 dysgraphia 9.8
426 angiokeratoma 9.8
427 trachea carcinoma 9.8
428 mitral valve disease 9.8
429 periodontitis 9.8
430 cataract 9.8
431 polycythemia 9.8
432 herpes simplex 9.8
433 subacute delirium 9.8
434 lupus erythematosus 9.8
435 amebiasis 9.8
436 acute myocardial infarction 9.8
437 hypereosinophilic syndrome 9.8
438 binswanger's disease 9.8
439 congenital hydrocephalus 9.8
440 light chain deposition disease 9.8
441 neurosyphilis 9.8
442 pulmonary arterio-veinous fistula 9.8
443 weber syndrome 9.8
444 clopidogrel resistance 9.8
445 angiomatosis 9.8
446 cerebral atrophy 9.8
447 cerebral hypoxia 9.8
448 dysphagia 9.8
449 spasticity 9.8
450 rapidly involuting congenital hemangioma 9.8
451 low-grade astrocytoma 9.8
452 toxic encephalopathy 9.7 MAP2 IL1B GRIN2A CASP3
453 sudden sensorineural hearing loss 9.7 MTHFR APOH
454 psychotic disorder 9.7 SLC1A1 MTHFR DRD1
455 large intestine cancer 9.6 ODC1 MTHFR IL1B CASP3
456 nervous system disease 9.5 IL1B CCL2 CASP3
457 retinal vascular occlusion 9.4 MTHFR CCL2 APOH
458 retinal vein occlusion 9.4 MTHFR CCL2 APOH

Comorbidity relations with Transient Cerebral Ischemia via Phenotypic Disease Network (PDN): (showing 86, show less)


Active Peptic Ulcer Disease Acute Cystitis
Acute Myocardial Infarction Alzheimer Disease
Anxiety Aortic Atherosclerosis
Aortic Valve Disease 1 Atrioventricular Block
Basilar Artery Insufficiency Benign Essential Hypertension
Bronchitis Bronchopneumonia
Cerebral Atherosclerosis Cerebral Degeneration
Cerebrovascular Disease Chronic Maxillary Sinusitis
Communicating Hydrocephalus Conjunctivitis
Conversion Disorder Cystitis
Decubitus Ulcer Deficiency Anemia
Diabetic Polyneuropathy Dysthymic Disorder
Encephalopathy Epilepsy, Focal, with Speech Disorder and with or Without Mental Retardation
Esophagitis Facial Paralysis
Familial Atrial Fibrillation First-Degree Atrioventricular Block
Generalized Atherosclerosis Gout
Heart Disease Hyperlipoproteinemia, Type Iv
Hypertension, Essential Hypertensive Encephalopathy
Hypoglycemia Hypoglycemic Coma
Hypothyroidism Inner Ear Disease
Intermediate Coronary Syndrome Intracranial Embolism
Intracranial Thrombosis Iron Deficiency Anemia
Kidney Disease Labyrinthitis
Left Bundle Branch Hemiblock Macular Degeneration, Age-Related, 1
Major Depressive Disorder Malignant Essential Hypertension
Meniere Disease Microvascular Complications of Diabetes 1
Migraine with Aura Migraine with or Without Aura 1
Mitral Valve Disease Mitral Valve Stenosis
Mononeuropathy of the Median Nerve, Mild Neurogenic Bladder
Obstructive Hydrocephalus Osteoarthritis
Osteoporosis Parkinson Disease, Late-Onset
Peripheral Vascular Disease Pernicious Anemia
Postinflammatory Pulmonary Fibrosis Primary Polycythemia
Progressive Familial Heart Block, Type Ia Protein-Energy Malnutrition
Pseudobulbar Palsy Pulmonary Valve Disease
Renal Artery Atheroma Rheumatic Heart Disease
Right Bundle Branch Block Schizophreniform Disorder
Sinoatrial Node Disease Spastic Hemiplegia
Status Epilepticus Subclavian Steal Syndrome
Swallowing Disorders Temporal Arteritis
Transient Global Amnesia Transient Retinal Arterial Occlusion
Tricuspid Valve Disease Vertebral Artery Insufficiency
Vertigo, Benign Recurrent Viral Labyrinthitis

Graphical network of the top 20 diseases related to Transient Cerebral Ischemia:



Diseases related to Transient Cerebral Ischemia

Symptoms & Phenotypes for Transient Cerebral Ischemia

UMLS symptoms related to Transient Cerebral Ischemia:


seizures, tremor, angina pectoris, edema, chest pain, back pain, amaurosis fugax, pain, headache, syncope, chronic pain, sciatica, vertigo/dizziness, sleeplessness, transient ischemic attacks, differing symptoms, transient ischemic attacks, stereotypic symptoms

MGI Mouse Phenotypes related to Transient Cerebral Ischemia:

46 (showing 1, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 9.32 BAD CASP3 DRD1 GRIN2A HSPA4 IL1B

Drugs & Therapeutics for Transient Cerebral Ischemia

Drugs for Transient Cerebral Ischemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 332, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
2
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
3
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
4
Acenocoumarol Approved, Investigational Phase 4 152-72-7 9052 54676537
5
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
6
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
7
Sodium citrate Approved, Investigational Phase 4 68-04-2
8
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
9
Nicotine Approved Phase 4 54-11-5 942 89594
10
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
11
Bupropion Approved Phase 4 34841-39-9, 34911-55-2 444
12
Amlodipine Approved Phase 4 88150-42-9 2162
13
Metformin Approved Phase 4 657-24-9 4091 14219
14
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
15
Olmesartan Approved, Investigational Phase 4 144689-63-4, 144689-24-7 130881 158781
16
Quinapril Approved, Investigational Phase 4 85441-61-8 54892
17
Sirolimus Approved, Investigational Phase 4 53123-88-9 6436030 5284616 46835353
18
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
19
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
20
Tranexamic Acid Approved Phase 4 1197-18-8 5526
21
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
22
Simvastatin Approved Phase 4 79902-63-9 54454
23
Angiotensin II Approved, Investigational Phase 4 11128-99-7, 68521-88-0, 4474-91-3 172198
24
Allopurinol Approved Phase 4 315-30-0 2094
25
Losartan Approved Phase 4 114798-26-4 3961
26
Pravastatin Approved Phase 4 81093-37-0 54687
27
Atorvastatin Approved Phase 4 134523-00-5 60823
28
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
29
Lisinopril Approved, Investigational Phase 4 83915-83-7, 76547-98-3 5362119
30
Ethanol Approved Phase 4 64-17-5 702
31
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
32
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
33
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
34
Serine Approved, Nutraceutical Phase 4 56-45-1 5951
35
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
36
Candesartan Experimental Phase 4 139481-59-7 2541
37
Dabigatran Investigational Phase 4 211914-51-1
38 3-n-butylphthalide Phase 4
39 Neuroprotective Agents Phase 4
40 Prasugrel hydrochloride Phase 4 389574-19-0
41 Radiation-Protective Agents Phase 4
42 Sildenafil Citrate Phase 4 171599-83-0
43 Citrate Phase 4
44 Phosphodiesterase 5 Inhibitors Phase 4
45 Vardenafil Dihydrochloride Phase 4
46 Vitamins Phase 4
47 Vitamin B Complex Phase 4
48 Vitamin B9 Phase 4
49 Folate Phase 4
50 Micronutrients Phase 4
51 Nutrients Phase 4
52 Trace Elements Phase 4
53 Phosphodiesterase Inhibitors Phase 4
54 Vasodilator Agents Phase 4
55 Central Nervous System Stimulants Phase 4
56 Hemostatics Phase 4
57 Vasoconstrictor Agents Phase 4
58 calcium heparin Phase 4
59 Cholinergic Agents Phase 4
60 Nicotinic Agonists Phase 4
61 Antifibrinolytic Agents Phase 4
62
Olmesartan medoxomil Phase 4 144689-63-4 130881
63 Antibiotics, Antitubercular Phase 4
64 Antifungal Agents Phase 4
65 Cytochrome P-450 CYP2C9 Inhibitors Phase 4
66 Cytochrome P-450 CYP3A Inhibitors Phase 4
67 Cytochrome P-450 Enzyme Inhibitors Phase 4
68 14-alpha Demethylase Inhibitors Phase 4
69 Steroid Synthesis Inhibitors Phase 4
70 Vitamin B3 Phase 4
71 Nicotinic Acids Phase 4
72 Analgesics Phase 4
73 Anti-Inflammatory Agents Phase 4
74 Analgesics, Non-Narcotic Phase 4
75 Cyclooxygenase Inhibitors Phase 4
76 Fibrinolytic Agents Phase 4
77 Anti-Inflammatory Agents, Non-Steroidal Phase 4
78 Platelet Aggregation Inhibitors Phase 4
79 Antipyretics Phase 4
80 Antirheumatic Agents Phase 4
81 Natriuretic Agents Phase 4
82 diuretics Phase 4
83 Angiotensin Receptor Antagonists Phase 4
84 Angiotensin II Type 1 Receptor Blockers Phase 4
85 Giapreza Phase 4
86 Angiotensinogen Phase 4
87 Free Radical Scavengers Phase 4
88 calcium channel blockers Phase 4
89 Diuretics, Potassium Sparing Phase 4
90 Adrenergic alpha-Antagonists Phase 4
91 Mineralocorticoid Receptor Antagonists Phase 4
92 Mineralocorticoids Phase 4
93 Vaccines Phase 4
94 Neurotransmitter Agents Phase 4
95 Peripheral Nervous System Agents Phase 4
96 Antihypertensive Agents Phase 4
97 Anticoagulants Phase 4
98 Protective Agents Phase 4
99 Adrenergic Agents Phase 4
100 Cardiotonic Agents Phase 4
101 Serine Proteinase Inhibitors Phase 4
102 HIV Protease Inhibitors Phase 4
103 Antithrombin III Phase 4
104
protease inhibitors Phase 4
105 Antithrombins Phase 4
106 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
107 Hypolipidemic Agents Phase 4
108 Anticholesteremic Agents Phase 4
109 Lipid Regulating Agents Phase 4
110 Antimetabolites Phase 4
111 Coagulants Phase 4
112 Calcium, Dietary Phase 4
113 Rosuvastatin Calcium Phase 4 147098-20-2
114 Autonomic Agents Phase 4
115 Adrenergic beta-1 Receptor Antagonists Phase 4
116 Adrenergic beta-Antagonists Phase 4
117 Angiotensin-Converting Enzyme Inhibitors Phase 4
118 Adrenergic Antagonists Phase 4
119 Sympatholytics Phase 4
120 Anti-Arrhythmia Agents Phase 4
121
Tocopherol Approved, Investigational Phase 3 1406-66-2, 54-28-4 14986
122
Phenprocoumon Approved, Investigational Phase 3 435-97-2 9908 54680692
123 fluindione Approved, Investigational Phase 3 957-56-2
124
Pioglitazone Approved, Investigational Phase 3 111025-46-8 4829
125
4-Aminopyridine Approved Phase 2, Phase 3 504-24-5 1727
126
Furosemide Approved, Vet_approved Phase 3 54-31-9 3440
127
Digoxin Approved Phase 3 20830-75-5 30322 2724385
128
Diltiazem Approved, Investigational Phase 3 42399-41-7 39186
129
Procainamide Approved Phase 3 51-06-9 4913
130
Propafenone Approved Phase 3 54063-53-5 4932
131
Sotalol Approved Phase 3 959-24-0, 3930-20-9 5253
132
Amiodarone Approved, Investigational Phase 3 1951-25-3 2157
133
Disopyramide Approved Phase 3 3737-09-5 3114
134
Quinidine Approved, Investigational Phase 3 56-54-2 441074
135
Verapamil Approved Phase 3 52-53-9 2520
136
Glimepiride Approved Phase 3 93479-97-1 3476